Acepodia

IPO

Acepodia® | POWERFUL, ACCESSIBLE CELL THERAPIES FOR PATIENTS WITH CANCER

Public · United States · Founded 2017 · $266.0M raised

Employees
51–200
Founded
2017
Business Model
B2B
Total Funding
$266.0M
Last Round
$100.0M Series DMar 2023
Rounds
4
Type
Public

About

Acepodia is a biotechnology company developing cell therapies for cancer. Its approach uses Antibody-Cell Conjugation technology to equip gamma delta T cells and NK cells with tumor-targeting mechanisms. The company is developing off-the-shelf therapies intended to be immediately available to a broad group of patients, with the goal of making cancer treatment more accessible.

Summary

Acepodia is a Biotech company based in United States, founded in 2017. It has raised $266.0M in total across 4 rounds, most recently a $100.0M Series D round in Mar 2023. Investors include Ridgeback Capital, 8VC and DEFTA Partners.

Tech & App Stack

7 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Series DSeries DMar 2023
$100.0M

Sign up to see all 4 events

Funding: Series A through Series D. Amounts, valuations, and investors where available.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Acepodia on Indexed.vc
<a href="https://indexed.vc/companies/acepodia"><img src="https://indexed.vc/api/badge/company/acepodia" alt="Acepodia on Indexed.vc" width="260" height="76" /></a>